×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Session 4: The Drive Towards Pragmatism in Randomized Clinical Trials: Are We There Yet?
Session Chair(s)
James Harnett, PharmD, MS
Executive Director, Health Economics and Outcomes Research
Regeneron Pharmaceuticals, Inc. , United States
Debra Schaumberg, DrSc, MPH
Vice President and Global Head, Startegic Development Consulting Chair
Evidera | PPD, United States
Learning Objective : At the conclusion of this session, participants should be able to:- Describe the dimensions of pragmatism that can be considered in designing randomized clinical trials
- Discuss relevant examples of PCTs to support healthcare decision-making
- Identify challenges with PCTs and opportunities to address
Speaker(s)
Getting to Value
Mark J Cziraky, PharmD
Anthem HealthCore, United States
Vice President of Research
The Drive Towards Pragmatism in Randomized Clinical Trials: Are We There Yet?
Frank W. Rockhold, PhD, MSc
Duke Clinical Research Institute, Duke University Medical Center, United States
Professor of Biostatistics